Subsequently, the recruited immune cells present antigen-derived peptides in association with major histocompatibility complex (MHC) molecules to T lymphocytes which results in activation of CD4+ T helper cells, CD8+ cytotoxic T cells as well as B cells, and hence the initiation of an adaptive immunity eventually allowing the control of distant metastases and protection from tumour relapse (17–24). The gene discussed is CD4; the disease is neoplasm.